These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 2885346)

  • 1. Nifedipine in neuroleptic-refractory schizophrenia.
    Kramer MS; DeMaria P; Morrow R; DiJohnson C; Sheves P
    J Clin Psychopharmacol; 1987 Jun; 7(3):195-6. PubMed ID: 2885346
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum cholesterol and treatment-resistance in schizophrenia.
    Boston PF; Dursun SM; Zafar R; Reveley MA
    Biol Psychiatry; 1996 Sep; 40(6):542-3. PubMed ID: 8879475
    [No Abstract]   [Full Text] [Related]  

  • 3. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
    Kopala LC; Fredrikson D; Good KP; Honer WG
    Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of treatment refractory schizophrenia.
    Morrison DP
    Br J Psychiatry Suppl; 1996 Dec; (31):15-20. PubMed ID: 8968651
    [No Abstract]   [Full Text] [Related]  

  • 5. Pipotiazine palmitate: a new depot neuroleptic.
    Simpson GM; Varga V
    Curr Ther Res Clin Exp; 1975 Mar; 17(3):276-80. PubMed ID: 236151
    [No Abstract]   [Full Text] [Related]  

  • 6. [Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia].
    Lombertie ER; Durelle G; Fuseau A
    Ann Med Psychol (Paris); 1995 Oct; 153(8):531-4. PubMed ID: 8561400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anxiolytic properties of neuroleptic drugs.
    Balon R; Kabès J
    Agressologie; 1981 Nov; 22(D):9-10. PubMed ID: 6120666
    [No Abstract]   [Full Text] [Related]  

  • 8. [Report on an open investigation on bromperidol, a neuroleptic of the butyrophenone series].
    Fleischhauer J
    Int Pharmacopsychiatry; 1978; 13 Suppl 1():30-7. PubMed ID: 35476
    [No Abstract]   [Full Text] [Related]  

  • 9. Predictors of neuroleptic treatment response in acute schizophrenia: results of a treatment study with perazine.
    Gaebel W; Pietzcker A; Ulrich G; Schley J; Müller-Oerlinghausen B
    Pharmacopsychiatry; 1988 Nov; 21(6):384-6. PubMed ID: 2907645
    [No Abstract]   [Full Text] [Related]  

  • 10. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
    Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
    Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of beta-endorphin under chronic neuroleptic treatment in schizophrenic patients: failure of naloxone to counteract curative effects of neuroleptic drugs.
    Emrich HM; Höllt V; Bergmann M; Kissling W; Schmid W; Zerssen DV; Herz A
    Adv Biochem Psychopharmacol; 1980; 22():489-502. PubMed ID: 6104902
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment refractory schizophrenia].
    Vanelle JM
    Encephale; 1995 Jun; 21 Spec No 3():13-21. PubMed ID: 7628336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proceedings: Butaclamol in the treatment of schizophrenia--a comparison of two treatment methods.
    Imaz F; Ban TA; Lehmann HE
    Psychopharmacol Bull; 1976 Jan; 12(1):31-4. PubMed ID: 1826
    [No Abstract]   [Full Text] [Related]  

  • 15. Factors which can make patients difficult to treat.
    Kane JM
    Br J Psychiatry Suppl; 1996 Dec; (31):10-4. PubMed ID: 8968650
    [No Abstract]   [Full Text] [Related]  

  • 16. [Arguments for early treatment of refractory schizophrenia].
    Lombertie ER; Salome N; Villegier P; Laghrissi-Thode F; Nassif F
    Encephale; 1995 Jun; 21 Spec No 3():29-33. PubMed ID: 7628338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients.
    van Berckel BN; Hijman R; van der Linden JA; Westenberg HG; van Ree JM; Kahn RS
    Biol Psychiatry; 1996 Dec; 40(12):1298-300. PubMed ID: 8959296
    [No Abstract]   [Full Text] [Related]  

  • 18. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
    Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
    Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 20. Piperacetazine in ambulatory chronic schizophrenic patients.
    Rada RT; Donlon PT
    Curr Ther Res Clin Exp; 1974 Feb; 16(2):124-9. PubMed ID: 4156665
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.